Morphic to Participate in Jefferies Global Healthcare Conference
Morphic to Participate in Jefferies Global Healthcare Conference
WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will take part in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5th, at 10:30 AM ET.
2024年5月31日，美國馬薩諸塞州沃爾瑟姆市（GLOBE NEWSWIRE）-- Morphic Therapeutic（納斯達克：MORF）是一家生物技術公司，致力於開發新一代可口服整合素療法以治療嚴重慢性疾病。該公司今天宣佈，其管理團隊成員將參加2024年傑富瑞全球醫療保健會議上的爐邊聊天，時間是北京時間6月5日週三上午10:30 。th。
A live webcast of the panel discussion and fireside chat at the Jefferies Global Healthcare Conference will be available on the Investor section of Morphic's website at www.morphictx.com. An archived replay will be available on the company's website following the conference.
傑富瑞全球醫療保健會議上的座談會和爐邊聊天將在Morphic網站的投資者專區進行現場網絡直播，網址爲www.morphictx.com。會後，公司網站將提供會議的存檔重播。
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company's unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.
關於Morphic Therapeutic
Morphic Therapeutic是一家生物製藥公司，致力於開發口服整合素療法組合以治療自身免疫、心血管、代謝性疾病、纖維化和癌症等嚴重慢性疾病。Morphic還在與Schrödinger合作，利用其專有的MInT技術平台推進其流水線和發現活動，該平台利用公司對整合素結構和生物學的獨特理解。欲獲得更多信息，請訪問：www.morphictx.com.
Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718
聯繫方式
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718
譯文內容由第三人軟體翻譯。